FealtySign in

CLOROX CO /DE/

(CLX)

CIK 21076 · SEC filings only

Not gradedDividend record
shown as history
company entity
65 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

65 declarations · 13 raised · 43 held · 0 cut · held 56 quarters

  1. HELD$1.2400/shperiod ended 2026-03-31Filing ↗
  2. NOTED$1.2400/shperiod ended 2025-12-31Filing ↗
  3. NOTED$2.4800/shperiod ended 2025-09-30Filing ↗
  4. HELD$1.2200/shperiod ended 2025-03-31Filing ↗
  5. NOTED$1.2200/shperiod ended 2024-12-31Filing ↗
  6. NOTED$2.4400/shperiod ended 2024-09-30Filing ↗
  7. HELD$1.2000/shperiod ended 2024-03-31Filing ↗
  8. NOTED$1.2000/shperiod ended 2023-12-31Filing ↗
  9. NOTED$2.4000/shperiod ended 2023-09-30Filing ↗
  10. HELD$1.1800/shperiod ended 2023-03-31Filing ↗
  11. NOTED$1.1800/shperiod ended 2022-12-31Filing ↗
  12. NOTED$2.3600/shperiod ended 2022-09-30Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
1 resolved promise

Not enough resolved promises to grade

1 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Credibility timeline

KEPT · Nov 2, 2020
20202020
Timeline as a list
  • Nov 2, 2020KEPTthe company currently plans to repurchase about half the full amount in fiscal year 2019
1 resolved buyback promise · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
BGuidance record
grade
company entity
12 resolved promises

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance shown, not graded (44)

These are non-GAAP forecasts. There is no comparable GAAP figure in SEC XBRL to check them against, so we show what was said — with its source filing — but never score it.

  1. eps guidance fy · Aug 3, 2026
    Adjusted EPS is expected to be between $5.70 and $6.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Apr 30, 2026
    Adjusted EPS is now expected to be between $5.45 and $5.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Feb 3, 2026
    Adjusted EPS is still expected to be between $5.95 and $6.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Feb 3, 2026
    Fiscal year diluted EPS is still expected to be between $5.60 and $5.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Nov 3, 2025
    Fiscal year diluted EPS is still expected to be between $5.60 and $5.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Nov 3, 2025
    Adjusted EPS is still expected to be between $5.95 and $6.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Jul 31, 2025
    Adjusted EPS is expected to be between $5.95 and $6.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · May 5, 2025
    Adjusted EPS is expected to be between $6.95 and $7.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. revenue guidance fy · May 5, 2025
    Organic sales are now expected to grow 4% to 5%
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Feb 3, 2025
    Adjusted EPS is now expected to be between $6.95 and $7.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Oct 30, 2024
    Adjusted EPS is now expected to be between $6.65 and $6.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Aug 1, 2024
    Adjusted EPS is expected to be between $6.55 and $6.80
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Apr 30, 2024
    Adjusted EPS is now expected to be between $5.80 and $5.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Feb 1, 2024
    Adjusted EPS is now expected to be between $5.30 and $5.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Feb 1, 2024
    fiscal year diluted EPS is now expected to be between $3.06 and $3.26
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Nov 1, 2023
    fiscal year diluted EPS is now expected to be between $2.10 and $2.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Nov 1, 2023
    Adjusted EPS is now expected to be between $4.30 and $4.80
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance q · Oct 4, 2023
    Adjusted EPS is expected to be a loss of $0.40 to $0.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Aug 2, 2023
    Adjusted EPS is expected to be between $5.60 and $5.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · May 2, 2023
    Adjusted EPS is now expected to be between $4.35 and $4.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · May 2, 2023
    Diluted EPS is now expected to be between $0.45 and $0.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance fy · Feb 2, 2023
    Adjusted EPS is now expected to be between $4.05 and $4.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. eps guidance fy · Nov 1, 2022
    Adjusted EPS between $3.85 and $4.22
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. eps guidance fy · Aug 3, 2022
    Adjusted EPS is expected to be between $3.85 and $4.22
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. eps guidance fy · May 2, 2022
    Adjusted EPS is now expected to be between $4.05 and $4.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. eps guidance fy · Feb 3, 2022
    Adjusted EPS between $4.25 and $4.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. eps guidance fy · Nov 1, 2021
    Adjusted EPS between $5.40 and $5.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  28. eps guidance fy · Nov 1, 2021
    Diluted EPS between $5.05 and $5.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  29. eps guidance fy · Aug 3, 2021
    Adjusted EPS is projected to be between $5.40 and $5.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  30. eps guidance fy · Apr 30, 2021
    and adjusted EPS to increase between 1% and 4%, or $7.45 to $7.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  31. eps guidance fy · Feb 4, 2021
    Clorox now anticipates fiscal year 2021 diluted EPS to increase between 9% and 12%, or $8.05 to $8.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  32. eps guidance fy · Nov 2, 2020
    Clorox now anticipates fiscal year 2021 diluted EPS to increase between 5% and 8%, or $7.70 to $7.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  33. eps guidance fy · Aug 3, 2020
    Net of all these factors, Clorox anticipates fiscal year 2021 diluted EPS range is expected to be from a mid-single-digit decrease to a mid-single-digit increase
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  34. eps guidance fy · Feb 4, 2020
    $6.10-$6.25 diluted EPS range
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  35. eps guidance fy · Aug 1, 2019
    Clorox anticipates fiscal year 2020 diluted EPS from continuing operations to be in the range of $6.30 to $6.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  36. eps guidance fy · May 1, 2019
    Clorox now expects fiscal year 2019 diluted EPS from continuing operations to be in the range of $6.25 to $6.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  37. eps guidance fy · Feb 4, 2019
    Net of all these factors, Clorox expects fiscal year 2019 diluted EPS from continuing operations to remain in the range of $6.20 to $6.40
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  38. eps guidance fy · Aug 2, 2018
    Clorox anticipates fiscal year 2019 diluted EPS from continuing operations to be in the range of $6.32 to $6.52
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  39. eps guidance fy · May 2, 2018
    Clorox now anticipates fiscal year 2018 diluted EPS from continuing operations to be in the range of $6.15 to $6.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  40. eps guidance fy · Nov 1, 2017
    Clorox now anticipates fiscal year 2018 diluted EPS from continuing operations to be in the range of $5.47 to $5.67
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  41. eps guidance fy · Nov 2, 2016
    Clorox now anticipates fiscal year 2017 diluted EPS from continuing operations to be in the range of $5.23 to $5.43
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  42. eps guidance fy · Nov 2, 2016
    Excluding the benefit of adopting the accounting standards update, Clorox continues to anticipate fiscal year 2017 diluted EPS from continuing operations to be in the range of $5.13 to $5.28
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  43. eps guidance fy · Jul 15, 2008
    The company now anticipates fiscal 2008 diluted EPS in the range of $3.22-$3.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  44. eps guidance fy · Feb 4, 2008
    the company’s outlook for diluted EPS is now in the range of $3.20 to $3.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (9) · 31 superseded

Open · revenue guidance fy

For fiscal year 2008, Clorox now anticipates sales growth in the range of 6-7 percent

unresolved — no outcome on filereceipt →
Open · revenue guidance q

Fourth-quarter sales are expected to be in the range of 10-11 percent

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Clorox continues to anticipate delivering 2 percent to 4 percent sales growth in fiscal year 2017

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Clorox now anticipates fiscal year 2018 sales growth at about 3 percent

unresolved — no outcome on file$3.0000receipt →
Open · revenue guidance fy

The company continues to expect net sales to be down low single digits.

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

The company now expects net sales to be down about 6%

resolves in ~198 daysreceipt →
Open · eps guidance fy

Fiscal year diluted EPS is now expected to be between $4.78  and $4.98

resolves in ~198 daysreceipt →
Open · eps guidance fy

Diluted EPS is expected to be between $5.41 and $5.71

resolves in ~564 daysreceipt →
Open · revenue guidance fy

Net sales are expected to be up 13% to 14% compared to the prior year

resolves in ~564 daysreceipt →
Superseded · eps guidance fy

Diluted EPS is expected to be between $4.65 and $4.95

revised by a later guidancereceipt →
Superseded · eps guidance fy

Clorox anticipates fiscal year 2022 diluted EPS to be between $5.05 and $5.35

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Net sales are expected to be flat to up 2% compared to the prior year.

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Net sales are now expected to be down low single digits

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Clorox’s fiscal year sales are now expected to grow between 10% and 13%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

The company still expects net sales to be down 6% to 10%

revised by a later guidancereceipt →
Superseded · eps guidance fy

Diluted EPS is expected to be between $4.95 and $5.20

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Clorox anticipates sales growth ranging from flat to 2%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Net sales are expected to be down 6% to 10% compared to the prior year.

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Net sales are now expected to be between a 2% decrease to a 1% increase

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Clorox’s fiscal year sales are now expected to grow between 5% and 9%

revised by a later guidancereceipt →
Superseded · eps guidance fy

Diluted EPS is expected to be between $3.10 and $3.47

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Net sales are expected to be flat to down 2% compared to the prior year.

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Clorox anticipates sales growth ranging from flat to low single digits

revised by a later guidancereceipt →
Superseded · eps guidance fy

Fiscal year diluted EPS is now expected to be between $5.52 and $5.92

revised by a later guidancereceipt →
Superseded · revenue guidance fy

The company continues to expect net sales to be flat to down 2%

revised by a later guidancereceipt →
Superseded · eps guidance fy

Diluted EPS between $3.80 and $4.05

revised by a later guidancereceipt →
Superseded · eps guidance fy

Fiscal year diluted EPS is now expected to be between $5.17 and $5.42

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Net sales decline of 1% to 4%

revised by a later guidancereceipt →
Superseded · eps guidance fy

Diluted EPS between $3.10 and $3.47

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Clorox now anticipates sales growth in the range of 1 percent to 3 percent

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Clorox’s 2022 fiscal year sales are projected to be down 2% to 6%

revised by a later guidancereceipt →
Superseded · eps guidance fy

Diluted EPS is expected to be between $5.60 and $5.95

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Net sales decline of 2% to 6%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Net sales from a 4% decrease to a 2% increase compared to the prior year

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Net sales are now expected to be down mid- to high single digits

revised by a later guidancereceipt →
Superseded · revenue guidance fy

The company now expects net sales to be down 1% to up 2%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Clorox continues to anticipate sales growth in the range of 2 to 4 percent

revised by a later guidancereceipt →
Superseded · revenue guidance fy

The company still expects net sales to be down 6% to 10%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Net sales are expected to be down 4% to up 2% compared to the prior year.

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Clorox anticipates sales growth in the range of 2 percent to 4 percent

revised by a later guidancereceipt →

Credibility timeline

UNRESOLVABLE · May 1, 2019BEAT · Aug 13, 2020MISSED · Aug 10, 2021MISSED · Aug 10, 2021KEPT · Aug 10, 2022KEPT · Aug 10, 2022BEAT · Aug 10, 2023MISSED · Aug 10, 2023BEAT · Nov 1, 2023BEAT · Nov 1, 2023BEAT · Aug 8, 2024BEAT · Aug 8, 2025BEAT · Aug 8, 2025
20192025
Timeline as a list
  • May 1, 2019UNRESOLVABLEClorox now anticipates sales growth in the range of 2% to 3%
  • Aug 13, 2020BEATLow single-digit decrease to 1% increase in sales
  • Aug 10, 2021MISSEDClorox’s fiscal year sales are still expected to grow between 10% and 13%
  • Aug 10, 2021MISSEDNet of all these factors, Clorox now anticipates fiscal year 2021 diluted EPS to decrease between 19% and 16%, or $5.94 to $6.14
  • Aug 10, 2022KEPTNet sales are still expected to decrease 1% to 4%
  • Aug 10, 2022KEPTDiluted EPS is now expected to be between $3.60 and $3.85
  • Aug 10, 2023BEATNet sales are now expected to be between a 1% and 2% increase
  • Aug 10, 2023MISSEDDiluted EPS is now expected to be between $3.20 and $3.45
  • Nov 1, 2023BEATNet sales are expected to decrease by 28% to 23% from the year-ago quarter.
  • Nov 1, 2023BEATDiluted net earnings per share (diluted EPS) is expected to be between a loss of $0.75 to a loss of $0.35.
  • Aug 8, 2024BEATfiscal year diluted EPS is now expected to be between $1.66 and $1.81
  • Aug 8, 2025BEATThe company now expects net sales to be down 1% to flat
  • Aug 8, 2025BEATFiscal year diluted EPS is now expected to be between $5.73 and $6.13
12 resolved guidance promises · 45dropped (couldn't be resolved on a consistent basis) · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →